Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca® (filgotinib) Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications;
Gilead to Receive Royalties on European Sales Starting in 2024 Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU
Galapagos webcast presentation tomorrow, 16 December 2020, at 14:00 CET / 8 AM ET,
Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca(R) (filgotinib) marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.